# Inspire Medical Systems Inc. (INSP)

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-29  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/INSP/primer

## Business Model

---
source: coverage-next-full
ticker: INSP
step: "01"
title: Business Overview — What Inspire Medical Systems Does
created: 2026-05-29
---

### Step 01 — Business Overview

#### Company Summary

Inspire Medical Systems, Inc. (NYSE: INSP) is a Golden Valley, Minnesota–based medical device company that develops and commercializes a neurostimulation therapy for moderate-to-severe obstructive sleep apnea (OSA). Founded in 2007 and FDA-cleared in 2014, Inspire sells a single commercial product — the **Inspire upper airway stimulation (UAS) system** — an implantable medical device that stimulates the hypoglossal nerve to prevent airway collapse during sleep.

Inspire is essentially a one-product, one-disease company at the commercial stage. It has no diversification across indications or product lines, though it runs pipeline programs for next-generation devices and potential label expansions.

---

#### The Product: Inspire UAS System

The Inspire system consists of three implanted components surgically placed in a ~90-minute outpatient procedure:

1. **Neurostimulator (IPG):** Small, battery-powered device implanted in the upper chest (subcutaneous). Contains sensing circuitry and delivers electrical stimulation pulses.
2. **Sensing Lead:** Placed between intercostal muscles; detects respiratory effort (breathing effort = indirect proxy for need for stimulation).
3. **Stimulation Lead:** Delivers stimulation to the hypoglossal nerve (the nerve that controls tongue muscle), which protrudes the tongue and opens the airway.

The patient controls the device via a **handheld remote control** — they turn it on before bed and off upon waking. The remote is a consumable, with battery replacement every 1–2 years providing a modest recurring revenue stream (though the overwhelming majority of revenue is implant kits).

**Inspire V** (launched 2023–2024) is the latest generation device — smaller, with Bluetooth connectivity and a smartphone app for patient control and compliance monitoring.

---

#### Clinical Indication & Patient Selection

- **Approved indication:** Moderate-to-severe OSA (AHI ≥15) in adults who are CPAP non-adherent or intolerant
- **FDA clearance:** 2014 (original); multiple subsequent PMA supplements expanding indication
- **Key inclusion criteria:** BMI generally ≤35 (historically; more recently expanded); absence of complete concentric collapse at velopalate (DISE criterion)
- **Patient pool:** ~30 million Americans with moderate-to-severe OSA; roughly 40–50% are CPAP non-adherent; Inspire estimates an addressable U.S. TAM of ~$6–8B (implant + follow-up)

**Clinical evidence:**
- STAR Trial (pivotal): 68% reduction in AHI at 12 months; published in NEJM (2014)
- ADHERE registry: Real-world effectiveness consistent with pivotal data
- Long-term follow-up (5-year): Durable response maintained

---

#### Business Model

**Revenue per procedure:** ~$25,000–$30,000 average selling price (ASP) for the Inspire system kit (3-lead set + IPG). ASP driven by U.S. hospital/ASC purchasing; international ASP varies by market.

**Revenue model breakdown (estimated):**
- **~95%+ of revenue:** Implant kit sales (capital equipment + disposable system, billed per procedure)
- **~<5% of revenue:** Remote controls, accessories (consumable replacements), and other

**Hospital/ASC customer model:**
- Inspire sells directly to hospitals and ambulatory surgery centers (ASCs)
- Procedures performed by ENT surgeons and sleep surgeons
- **Embedded sales rep model:** Inspire "therapy consultants" attend procedures to coach surgeons — highly labor-intensive but critical for adoption

**Pricing and reimbursement:**
- Covered by Medicare/CMS under CPT codes (recently disrupted — see Step 11 risks)
- Covered by most commercial payers (15,000+ payer contracts)
- Prior authorization (PA) is required; high PA burden reduces physician conversion

---

#### Geographic Footprint

| Region | Estimated Revenue Share | Key Markets |
|--------|------------------------|-------------|
| United States | ~77–80% | Nationwide hospital/ASC network |
| Europe | ~15–18% | Germany, France, Netherlands, UK |
| Asia-Pacific | ~3–5% | Japan (recently launched), Australia |
| Rest of World | <2% | Emerging expansion |

As of FY 2025, Inspire has implant capability at ~1,500+ U.S. centers and ~500+ international centers. International expansion is a multi-year growth driver as markets mature.

---

#### Segments

Inspire operates as a **single reportable segment** — medical device sales of the UAS system. There are no separate reportable divisions.

---

#### Employees & Organizational Profile

- ~2,500 employees (estimated, FY 2025)
- Heavy weighting toward direct sales force (therapy consultants, account managers)
- Significant headcount growth 2020–2024 as salesforce scaled; some normalization expected in 2026 with revenue guidance reduction

---

#### Capital Markets Profile

- **IPO:** 2018 (NYSE)
- **Market Cap (May 2026):** ~$1.25B
- **Share Count:** ~28.6M shares basic
- **Float:** High institutional ownership; ~14% SBC dilution annual rate (elevated)
- **Stock performance:** $24 at IPO → ~$285 peak (2021) → ~$43 (May 2026) — massive drawdown driven by growth deceleration, GLP-1 drug competition, and reimbursement headwinds

---

#### Mission & Strategic Positioning

Inspire's stated mission is to "improve the lives of people suffering from obstructive sleep apnea." Its strategic positioning rests on being the only commercially mature implantable neuromodulation therapy for OSA — a device that treats the anatomical root cause of airway obstruction rather than masking symptoms (as CPAP does) or performing irreversible structural surgery.

The company's strategic priorities as of 2025–2026:
1. Resolve near-term reimbursement disruption (CPT code + WISeR)
2. Continue international market expansion
3. Expand Inspire V adoption with digital health features
4. Defend against Nyxoah Genio (FDA-approved August 2025)
5. Execute $200M buyback authorized August 2025

## Financial Snapshot

---
source: coverage-next-full
ticker: INSP
step: "04"
title: Financial Snapshot — 3-Year P&L Summary
created: 2026-05-29
---

### Step 04 — Financial Snapshot (3-Year P&L)

#### Income Statement Summary

| Metric | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|--------|---------|---------|---------|---------|
| **Revenue** | $407.9M | $624.8M | $802.8M | $912.0M |
| YoY Growth | ~+92% | +53% | +28% | +14% |
| **Gross Profit** | $341.7M | $528.2M | $679.8M | $778.8M |
| **Gross Margin** | 83.8% | 84.5% | 84.7% | **85.4%** |
| **R&D Expense** | $68.6M | $116.5M | $114.1M | $103.2M |
| R&D % Revenue | 16.8% | 18.6% | 14.2% | 11.3% |
| **SG&A Expense** | $320.7M | $452.0M | $529.6M | $624.6M |
| SG&A % Revenue | 78.6% | 72.3% | 66.0% | 68.5% |
| **Operating Income** | -$47.6M | -$40.3M | $36.1M | $51.0M |
| **Operating Margin** | -11.7% | -6.5% | +4.5% | **+5.6%** |
| **Net Income** | -$44.9M | -$21.2M | $53.5M | $145.4M |
| **Net Margin** | -11.0% | -3.4% | +6.7% | **+15.9%** |
| **EPS (Diluted)** | -$1.60 | -$0.72 | $1.75 | $4.89 |
| **SBC** | $52.0M | $82.5M | $116.0M | $130.3M |
| SBC % Revenue | 12.7% | 13.2% | 14.5% | 14.3% |

**Source:** SEC EDGAR XBRL, CIK 0001609550

---

#### Key Financial Observations

##### Revenue Growth: Exceptional But Decelerating
Revenue has compounded from $28.6M in 2017 to $912M in 2025 — a 10-year CAGR of ~50%+ which is extraordinary for a medtech company. However, the trajectory is clearly decelerating: ~92% growth in 2022 → ~53% in 2023 → ~28% in 2024 → ~14% in 2025 → guidance of -4% to -9% in 2026. This deceleration reflects both law-of-large-numbers effects and specific 2025–2026 headwinds (reimbursement disruption, GLP-1 competition).

##### Gross Margins: Exceptional and Improving
Gross margins of 83.8%–85.4% are exceptional even by medtech standards. The improvement trend reflects:
- Operating leverage on manufacturing (despite outsourced assembly)
- Scale benefits on material costs
- Premium ASPs maintained with Inspire V launch
- Minimal COGS inflation impact given product complexity

These margins are structurally high because the implant is a complex engineered device sold at high ASP with minimal recurring COGS (no reagents, no disposables, minimal service cost).

##### Path to Operating Profitability: Achieved
Inspire turned operating cash flow positive in FY 2024 ($36.1M operating income) after years of losses. This was driven by revenue scaling past the break-even point on the fixed salesforce cost base. FY 2025 operating income improved to $51.0M (5.6% margin).

**Important caveat:** GAAP net income of $145.4M in FY 2025 vs. $51M operating income indicates ~$94M in non-operating income (primarily interest income on the large cash balance + tax benefits). This is not a sustainable GAAP earnings uplift.

##### SG&A: The Dominant Cost and the Moat
SG&A at ~66–79% of revenue is extreme by any standard. This primarily reflects the embedded sales rep model — Inspire employs ~1,000+ therapy consultants and account managers who attend procedures. This is not waste; it is the mechanism of adoption. New centers and new surgeons require intensive hand-holding.

The SG&A ratio has been declining from 78.6% (2022) → 66.0% (2024), demonstrating operating leverage as revenue scales over the fixed sales organization cost base. The 2025 uptick to 68.5% likely reflects salesforce investments that preceded the 2026 guidance reduction.

##### R&D: Tapering as Core Product Matures
R&D fell from 18.6% of revenue (2023 peak) to 11.3% (2025). This reflects: (1) completion of Inspire V development cycle, (2) ADHERE registry maturation, and (3) operating efficiency focus. Ongoing R&D investment includes next-generation IPG development and potential label expansions.

##### SBC: The Elephant in the Room
At 14.3% of revenue ($130.3M in FY 2025), SBC is very high relative to peers. This means:
- GAAP EPS of $4.89 in FY 2025 is after $130M SBC expense
- Cash-adjusted earnings (FCF per share) are a better profitability measure
- Adjusted EPS (non-GAAP) management guides to $0.75–$1.25 for FY 2026

---

#### Adjusted / Non-GAAP Profitability

Management reports non-GAAP adjusted income/EPS, excluding SBC and certain other items. Approximate adjusted metrics:

| Metric | FY 2024 | FY 2025 | FY 2026E |
|--------|---------|---------|----------|
| Adjusted Operating Income | ~$152M | ~$181M | ~$120–140M |
| Adjusted Operating Margin | ~19% | ~20% | ~14–17% |
| Adjusted EPS | ~$4.00 | ~$5.50 | $0.75–$1.25 |

*Note: The wide range on FY 2026 adj. EPS guidance ($0.75–$1.25) reflects significant reimbursement uncertainty. The implied adj. op. income contraction vs. 2025 reflects both revenue decline and continued SG&A investment to preserve salesforce capacity.*

---

#### COGS & Manufacturing

| Year | COGS | Gross Margin | COGS Per Revenue Dollar |
|------|------|-------------|------------------------|
| 2023 | $96.6M | 84.5% | $0.155 |
| 2024 | $123.0M | 84.7% | $0.153 |
| 2025 | $133.2M | 85.4% | $0.146 |

COGS efficiency improved modestly year over year. The Inspire system is manufactured by contract manufacturers with proprietary designs; Inspire does not own manufacturing assets. This asset-light model reduces capital intensity but creates some supply chain risk.

---

#### P&L Bridge: 2023 → 2025

```
                            FY 2023         FY 2025
Revenue                    $624.8M         $912.0M   (+$287M)
Gross Profit               $528.2M         $778.8M   (+$250M)
Operating Expenses         $568.5M         $727.8M   (+$159M)
  SG&A                     $452.0M         $624.6M   (+$173M)
  R&D                      $116.5M         $103.2M   (-$13M)
Operating Income           -$40.3M          $51.0M   (+$91M)
```

The operating leverage is visible: revenue grew $287M, gross profit grew $250M, and OpEx grew only $159M — yielding a $91M improvement in operating income. This is the core investment thesis: as revenue scales, operating leverage is significant given 85% gross margins.

---

#### Conclusion

Inspire is a high-gross-margin, scaling MedTech company that achieved operating profitability in FY 2024 after years of investment-phase losses. The path from FY 2023 (-$40M operating income) to FY 2025 ($51M) was achieved organically through revenue scaling, not cost cutting. The FY 2026 guidance reduction introduces near-term earnings pressure, but the underlying business model — high gross margins, durable clinical demand, underpenetrated market — remains intact.

The central financial risk is whether FY 2026 represents a temporary reimbursement-driven trough or the beginning of a structural deceleration. The answer determines whether INSP is deeply undervalued at ~1.4x EV/Revenue or fairly valued on long-run earnings expectations.

## Recent Catalysts

---
source: coverage-next-full
ticker: INSP
step: "12"
title: Catalysts — Near-Term Events and Bull/Bear Cases
created: 2026-05-29
---

### Step 12 — Catalysts

#### Near-Term Catalysts (6–18 Months)

##### Catalyst 1: CPT Code Resolution Path Clarity (2026–2027)

**What to watch:** AMA CPT Editorial Panel review process for new Category I code for Inspire V HNS procedures. Any interim announcements about the code timeline, preliminary physician fee valuation, or CMS acceptance of the new code would be significant positive catalysts.

**Expected timing:** New code targeted for January 1, 2028. Preliminary RVU (relative value unit) valuations from AMA could emerge in H2 2027. Earlier-than-expected timeline clarity would be strongly positive for sentiment.

**Upside scenario:** New code provides physician fee equivalent to or above the pre-transition baseline → Inspire V adoption resumes at prior growth rates → 2027 revenue significantly above current expectations.

**Downside scenario:** New code delayed or provides permanently lower physician fees → 2028+ revenue ceiling reduced.

---

##### Catalyst 2: WISeR Program Modification or Termination (2026)

**What to watch:** CMS quarterly policy updates; Congressional oversight of the WISeR mandatory PA program; any industry/medical association lobbying that modifies the program in 6 active states.

**Expected timing:** Uncertain. CMS pilot programs can run 2–3 years; modification requires CMS rulemaking. Any favorable modification (e.g., reduction in covered states, streamlined PA pathway, exemption for established Inspire centers) would be a positive surprise.

**Impact:** WISeR is creating ~15–30 day delays in 6 key states. Elimination would remove this friction in the highest-revenue markets.

---

##### Catalyst 3: Nyxoah Commercial Performance Data (Q2–Q3 2026)

**What to watch:** Nyxoah's first full commercial quarter results (expected Q2 2026 earnings). Procedure volumes, payer coverage progress, pricing, and market development spending will provide clarity on the competitive threat magnitude.

**Bullish scenario:** Nyxoah ramp is slow (<500 procedures in first quarter); limited payer coverage; high marketing costs → Inspire's competitive moat is demonstrated; market share anxiety reduced.

**Bearish scenario:** Nyxoah achieves rapid payer coverage (using same CPT code framework) and ramps 1,000+ procedures quickly → competitive concern intensifies.

---

##### Catalyst 4: Q2 2026 Earnings (August 2026)

**What to watch:** Q2 2026 is the first full quarter under the CPT code disruption + WISeR program. Revenue trajectory vs. Q2 2025 ($217M) will provide the most meaningful data point on how severe and durable the headwinds are.

- **If Q2 2026 > $205M** (~+5% floor beat): Market relief; headwind may be at the milder end of range
- **If Q2 2026 < $200M** (worse than Q1 2026 on a seasonally adjusted basis): Market concern; guidance may be at risk
- **International growth disclosure:** Any explicit breakout of international vs. U.S. growth would help separate structural demand from policy-driven U.S. weakness

---

##### Catalyst 5: GLP-1 Real-World OSA Data (Ongoing)

**What to watch:** Publication of real-world GLP-1 adherence and OSA response data (1–2 year follow-up). Key metrics: % of obese OSA patients achieving adequate AHI control from GLP-1 alone; GLP-1 discontinuation rates.

**Bullish for Inspire:** Real-world GLP-1 adherence poor; partial responders progress to Inspire; net new diagnosis effect positive → Inspire's addressable market not structurally impaired.

**Bearish for Inspire:** GLP-1 real-world efficacy matches trials; broad adoption; payers mandate GLP-1 first before Inspire approval → patient funnel to Inspire reduced.

---

##### Catalyst 6: Share Buyback Acceleration (Ongoing)

**What to watch:** Quarterly share repurchase activity vs. $200M authorization (expires August 2027). Aggressive buyback at ~$43 stock price significantly reduces outstanding share count and is accretive at current valuation.

**At $43/share:** $200M buyback could retire ~4.65M shares (~16% of current float) — dramatically accretive if completed. Management's willingness to accelerate buybacks at current prices is a signal of conviction in the business recovery.

---

##### Catalyst 7: International Market Expansion Milestones

**What to watch:** Japan procedure volumes; new country launches; European expansion into Eastern Europe or Nordic markets.

**Impact:** International growth (estimated +15–20% currently) is proving resilient to U.S. headwinds. Analyst upgrades on international momentum could revalue the stock even before U.S. recovery.

---

#### Bull Case

**Bull Case**
- CPT code disruption resolves in 2027–2028 with physician fees restored to or above pre-transition levels, triggering a sharp V-shaped recovery in U.S. procedure volumes; combined with continued international growth, revenue reaccelerates to $1.0B+ by 2027 and $1.2B+ by 2028, while operating leverage drives margins toward 15–20%, creating a dramatically earnings story at an entry price of only 1.4x EV/Revenue.
- GLP-1 drugs prove to be a net positive for Inspire's addressable market — driving mass OSA diagnosis among obese patients, the majority of whom experience only partial response from GLP-1 therapy and subsequently become ideal Inspire candidates, growing the treated-patient funnel rather than cannibalizing it.
- Nyxoah Genio achieves only modest commercial penetration (< 5% share) due to inferior evidence base, limited payer coverage, and Inspire's entrenched surgeon network and DTC brand — validating Inspire's moat and allowing the company to defend its dominant market position while executing the $200M buyback at deeply discounted prices.

**Bear Case**
- The CPT code disruption is more permanent than anticipated — the January 2028 new Category I code provides physician fees 20–30% below the pre-transition baseline, creating a structural reduction in physician economic incentive to perform Inspire procedures and permanently lowering the annual U.S. procedure ceiling.
- GLP-1 drugs penetrate 25–35% of the obese OSA market within 5 years, materially shrinking the CPAP non-adherent patient pool that is Inspire's core addressable population, while Nyxoah Genio simultaneously captures 10–15% of remaining HNS procedures with its less invasive leadless design — together eroding Inspire's dominant position and capping long-run revenue at $700–800M.
- Inspire's high fixed-cost salesforce model (SG&A ~68% of revenue) creates severe operating leverage in reverse during a prolonged revenue decline, with SBC remaining elevated (~$130M annually) as cash depletes, forcing either a dilutive equity raise, an aggressive cost-cutting program that undermines surgeon relationships, or both — compressing the stock toward 1x revenue or below.

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/insp
- Full research API: GET /api/v1/research/INSP/memo
- Coverage universe: /stocks